📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-10 13:14
0 analysed today
FollowTelegram
0
Today
151,853
All-time analysed
43,533
Positive
6,742
Negative
92,741
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
4 announcements match the current filters (relevance ≥ 5).
Amwill Health Care Secures CDSCO Approval to Import FoliColor Hair Colour Valid Upto Oct 2031
Amwill Health Care has secured a new regulatory licence from the Central Drugs Standard Control Organization (CDSCO) to import FoliColor- Oxidative hair colour (Black variant) into India. The registration certificate (RC/COS- 007631) is valid for five years from October 8, 2026, to October 7, 2031. This approval allows the company to commence import and commercial sales in India, adding to its product portfolio against a backdrop of TTM revenue of ₹85 crore. The counterparty or supplier is confirmed as a non-related party.
Confidence: HIGH
What changedAmwill Health Care obtained a 5-year CDSCO licence permitting the import and commercial distribution of FoliColor hair colour products in India.
Why it mattersEnables product line expansion in the cosmetic/haircare segment, supporting top-line growth opportunities beyond its pharmaceutical base.
Licence Validity Period: 08-Oct-2026 valid upto 07-Oct- 2031Certificate Number: RC/COS- 007631Date of Receipt: October 09, 2026Expected Revenue Impact: not disclosed
📅 Short termCommercial import operations can begin immediately, though initial revenue contribution may take a few quarters to reflect on the top line.
📈 Long termStrengthens product portfolio over the 5-year regulatory window, providing gradual cross-selling opportunities across domestic distribution channels.
⚠ Risk flags
- Market acceptance and competitive pressures in the consumer hair colour segment
- Revenue potential and rollout expenses not disclosed
Key Highlights
CDSCO granted import registration certificate No. RC/COS- 007631 for FoliColor hair colour (Black variant)
Licence valid for 5 years from October 8, 2026, upto October 7, 2031
Approval received by the company on October 9, 2026
Enables commercial import and retail sale in India with an unrelated party supplier
👀 What to Watch
Track the commercial launch timeline and monitor upcoming quarterly filings to see the revenue contribution from the FoliColor line relative to current TTM sales of ₹85 crore.
₹33 Cr Investment Limits Approved for Multi-Asset Treasury Strategy
Amwill Health Care has approved a new hybrid treasury strategy to deploy surplus cash from internal accruals into a multi-asset framework. The company has set aggregate limits totaling ₹33 crore across various asset classes, including debt, equity, and alternative investments. This total limit represents approximately 40.7% of the company's current net worth of ₹81 crore. The strategy aims to optimize post-tax, risk-adjusted returns while maintaining a base in traditional fixed deposits.
Confidence: HIGH
What changedThe company has formally shifted from a traditional bank-deposit-heavy treasury approach to an active multi-asset investment framework.
Why it mattersWith a net worth of ₹81 crore and zero debt, the company is seeking to enhance yields on its surplus capital; however, this introduces market and credit risk to a significant portion of the balance sheet.
Total Investment Limit: ₹33 CrLimit vs Net Worth: ~40.7%Private Credit/AIF Limit: ₹15 CrEquity/IPO Limit: ₹2 CrDebt/G-Sec Limit: ₹10 Cr
📅 Short termLikely neutral for the stock price as this is a capital allocation policy change rather than a direct impact on pharmaceutical operations.
📈 Long termIf executed well, it could improve non-operating income and overall PAT; however, high exposure to Private Credit and SME IPOs carries inherent risk for a company of this size.
⚠ Risk flags
- Credit risk in Private Credit/AIFs (₹15 Cr limit)
- Market volatility risk in Equity and SME IPO investments
- Potential distraction from core pharmaceutical operations
Key Highlights
Total investment limit of ₹33 crore approved across five distinct financial segments using internal accruals
Allocation of up to ₹15 crore (18.5% of Net Worth) for Private Credit Funds, AIFs, and Structured Debt
Limit of ₹2 crore set for investments in listed equity shares and both Mainboard and SME IPOs
Debt instruments including G-Secs, NCDs, and Commercial Papers capped at an aggregate of ₹10 crore
Additional ₹3 crore limits each for Mutual Fund SIPs and invoice discounting platforms
👀 What to Watch
Investors should monitor the 'Other Income' component in future quarterly results to evaluate the performance of this treasury strategy. It is important to watch if the management maintains focus on the core pharmaceutical business (TTM Revenue ₹85 Cr) while managing these financial assets.
Amwill Health Care Announces ₹0.50 Dividend and Re-appointment of MDs with ₹1.57 Cr Salary Each
Amwill Health Care has scheduled its 9th Annual General Meeting (AGM) for August 14, 2026, to approve a final dividend of ₹0.50 per share for FY 2025-26. A key agenda item is the re-appointment of two Managing Directors, Mr. Tarun Gandhi and Mr. Anand Gandhi, for five-year terms starting January 2027. Each MD is proposed to receive a basic salary of up to ₹1.572 Cr per annum, totaling ₹3.144 Cr for both. This combined maximum remuneration represents approximately 13.6% of the company's TTM PAT of ₹23 Cr.
Confidence: HIGH
What changedThe company has formalized its AGM schedule, dividend payout, and proposed a 5-year leadership extension for its Managing Directors with defined salary caps.
Why it mattersWhile the dividend provides a small yield, the significant management compensation (13.6% of TTM PAT) is a material recurring cost that shareholders must evaluate against the company's growth performance.
Final Dividend: ₹0.50 per shareIndividual MD Salary (Max): ₹1.572 Cr per annumCombined MD Salary vs TTM PAT: ~13.6%Combined MD Salary vs TTM Revenue: ~3.7%Record Date: August 08, 2026
📅 Short termThe stock may see minor activity around the August 08 record date for the dividend payout.
📈 Long termLeadership continuity is established for the next five years; however, the high ratio of management pay to net profit remains a structural point for long-term monitoring.
⚠ Risk flags
- High management remuneration relative to net profit (combined ~13.6% of TTM PAT)
Key Highlights
Proposed final dividend of ₹0.50 per equity share of ₹10 face value for FY 2025-26
Re-appointment of two Managing Directors for 5-year terms (2027-2032) with a maximum salary of ₹1.572 Cr each per annum
Combined maximum MD remuneration of ₹3.144 Cr accounts for ~3.7% of TTM Revenue (₹85 Cr)
Cut-off date for dividend and voting eligibility fixed for August 08, 2026
AGM to be held via Video Conferencing on August 14, 2026
👀 What to Watch
Investors should monitor the AGM voting results, specifically the approval of management remuneration, and track if future profit growth justifies the proposed salary levels.
₹0.50 Dividend and 5-Year Re-appointment of Managing Directors at Amwill Health Care
Amwill Health Care has scheduled its 9th Annual General Meeting (AGM) for August 14, 2026. The board has proposed a final dividend of ₹0.50 per equity share (5% of face value) for FY 2025-26. Key agenda items include the re-appointment of promoters Mr. Tarun Gandhi and Mr. Anand Gandhi as Managing Directors for five-year terms starting January 2027, with an annual salary cap of ₹1.572 Cr each. The combined MD remuneration of ₹3.14 Cr represents approximately 13.6% of the company's TTM PAT of ₹23 Cr.
Confidence: HIGH
What changedThe company has formalized its AGM schedule, dividend payout, and long-term leadership contracts for its promoter-directors.
Why it mattersThe announcement ensures leadership continuity for the next five years and provides a modest yield to shareholders, though the high management pay relative to profits is a key governance metric to track.
Proposed Dividend: ₹0.50 per shareCombined MD Remuneration: ₹3.14 CrRemuneration vs TTM PAT: ~13.6%Record Date: August 8, 2026AGM Date: August 14, 2026
📅 Short termThe stock may see minor activity around the record date (Aug 8) as investors position for the ₹0.50 dividend.
📈 Long termLeadership stability is confirmed through 2032; however, the high percentage of profit allocated to MD salaries may be a point of scrutiny if earnings growth slows.
⚠ Risk flags
- High management remuneration (13.6% of TTM PAT)
- Related-party re-appointments (Promoters)
Key Highlights
Proposed final dividend of ₹0.50 per equity share for the financial year ended March 31, 2026.
Re-appointment of Mr. Tarun Gandhi as Managing Director for a 5-year term (Jan 2027 - Jan 2032) at ₹1.572 Cr per annum.
Re-appointment of Mr. Anand Gandhi as Managing Director for a 5-year term (Jan 2027 - Jan 2032) at ₹1.572 Cr per annum.
Fixed August 8, 2026, as the cut-off date for dividend entitlement and e-voting eligibility.
Remote e-voting period scheduled from August 11 to August 13, 2026.
👀 What to Watch
Investors should note the August 8, 2026 record date for dividend eligibility and monitor the AGM voting results regarding the significant management remuneration levels.
